Research Site

Chermside 4032

2 studies enrolling now · 15 studies all time

What they study most

Advanced Clear Cell Renal Cell Carcinoma, Atherothrombosis, Biliary Tract Cancer, COPD (Chronic Obstructive Pulmonary Disease), Cardiovascular Death, Heart Failure With Preserved Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure and Impaired Kidney Function, Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer, Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV, Lung Cancer, Metastatic Castration-Sensitive Prostate Cancer

Studies at this site

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma — Recruiting now
• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Recruiting now
• Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents — Running, not enrolling
• MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma — Running, not enrolling
• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma — Running, not enrolling
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC — Running, not enrolling
• AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer — Completed
• A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% — Completed
• Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients — Completed
• Study of Verinurad in Heart Failure With Preserved Ejection Fraction — Completed
• Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy — Completed
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed